Healthy funding and scientific innovation are lifting profits for Illumina (ILMN), Thermo Fisher Scientific (TMO), Danaher (DHR), Agilent Technologies (A), and Bio-Techne (TECH), Darren Fonda writes in this week’s edition of Barron’s. These five life-sciences tools and equipment firms are benefiting from rising demand in a variety of areas, from lab work to the consumer market, the report noted, adding that they are poised to capitalize on medical innovation and demand for health care in emerging markets.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.